We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids
Read MoreHide Full Article
Vertex Pharmaceuticals Inc. (VRTX - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval for expanded use of Orkambi. The opinion is given for Orkambi (lumacaftor/ivacaftor) to treat children with cystic fibrosis (CF) aged two to five years who have two copies of the F508del mutation.
Approximately 1,500 people in Europe in this age group suffer from this most common form of CF disease, thus making Orkambi eligible to treat expanded patient populations.
Orkambi is already approved in the U.S. and Europe for the treatment of CF in patients aged six or older who have two copies of the F508del mutation. It was approved in the United States for the two to five years age group in August.
The CHMP opinion was based on data from a phase III open-label safety study in 60 patients that showed treatment with Orkambi to be generally well tolerated for 24 weeks, with a safety profile similar to that in patients aged 6 years or older.
The stock has gained 10.2% so far this year, against the 18% decline registered by the industry.
Sales of Orkambi were down 16.1% year over year in the third quarter of 2018 to $282 million due to a switch in patient base to Vertex’s third and newest CF medicine, Symdeko from Orkambi, which targets the same population. Orkambi revenues are expected to be hurt by this switch during the third quarter of 2018.
Other than Orkambi and Symdeko, Vertex also has Kalydeco (ivacaftor) in its CF product portfolio. We remind investors that, Symdeko is a combination of tezacaftor and ivacaftor, which was launched in the United States in February 2018 for treating CF patients. The drug has shown strong uptake so far.
The company is developing many new combination regimens with CFTR modulators. The CF correctors could bring in multi-billion dollar sales for Vertex.
Vertex is evaluating two next-generation CFTR correctors (VX-659 and VX-445) in phase III studies as part of a triple combination with tezacaftor and ivacaftor. Vertex is evaluating both the combinations in two separate studies for F508del/Min and F508del homozygous patients.
Both AbbVie (ABBV - Free Report) and Galapagos NV’s (GLPG - Free Report) were jointly developing CF product candidates, which included a triple regimen combination. However, last month, AbbVie announced that it is taking full commercial and development responsibility of all clinical/pre-clinical programs in cystic fibrosis products, which were originally discovered and developed in partnership with Galapagos.
AbbVie will now continue the development of the triple combination therapy for CF. Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) is developing a CF candidate, lenabasum, in a mid-stage study.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Vertex (VRTX) Gets Positive CHMP Opinion for Orkambi in Kids
Vertex Pharmaceuticals Inc. (VRTX - Free Report) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval for expanded use of Orkambi. The opinion is given for Orkambi (lumacaftor/ivacaftor) to treat children with cystic fibrosis (CF) aged two to five years who have two copies of the F508del mutation.
Approximately 1,500 people in Europe in this age group suffer from this most common form of CF disease, thus making Orkambi eligible to treat expanded patient populations.
Orkambi is already approved in the U.S. and Europe for the treatment of CF in patients aged six or older who have two copies of the F508del mutation. It was approved in the United States for the two to five years age group in August.
The CHMP opinion was based on data from a phase III open-label safety study in 60 patients that showed treatment with Orkambi to be generally well tolerated for 24 weeks, with a safety profile similar to that in patients aged 6 years or older.
The stock has gained 10.2% so far this year, against the 18% decline registered by the industry.
Sales of Orkambi were down 16.1% year over year in the third quarter of 2018 to $282 million due to a switch in patient base to Vertex’s third and newest CF medicine, Symdeko from Orkambi, which targets the same population. Orkambi revenues are expected to be hurt by this switch during the third quarter of 2018.
Other than Orkambi and Symdeko, Vertex also has Kalydeco (ivacaftor) in its CF product portfolio. We remind investors that, Symdeko is a combination of tezacaftor and ivacaftor, which was launched in the United States in February 2018 for treating CF patients. The drug has shown strong uptake so far.
The company is developing many new combination regimens with CFTR modulators. The CF correctors could bring in multi-billion dollar sales for Vertex.
Vertex is evaluating two next-generation CFTR correctors (VX-659 and VX-445) in phase III studies as part of a triple combination with tezacaftor and ivacaftor. Vertex is evaluating both the combinations in two separate studies for F508del/Min and F508del homozygous patients.
Both AbbVie (ABBV - Free Report) and Galapagos NV’s (GLPG - Free Report) were jointly developing CF product candidates, which included a triple regimen combination. However, last month, AbbVie announced that it is taking full commercial and development responsibility of all clinical/pre-clinical programs in cystic fibrosis products, which were originally discovered and developed in partnership with Galapagos.
AbbVie will now continue the development of the triple combination therapy for CF. Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) is developing a CF candidate, lenabasum, in a mid-stage study.
Vertex Pharmaceuticals Inc. Price
Vertex Pharmaceuticals Incorporated Price | Vertex Pharmaceuticals Incorporated Quote
Zacks Rank
Vertex is a Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>